Loading the section
Closing prices for 09 October 2026
Next earnings report: 04 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Charles River Laboratories International, Inc. trades on NYSE under the ticker CRL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks CRL has traded between 146.20 $ and 333.30 $. As of 09 October 2026 the price stood 83.16 % of the way from the 52-week low to the high.
Over one year CRL shares rose 73.97 %; over six months they rose 71.81 %. Volatility over 90 days is 40.95 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 3.5, below the sector median of 3.9. Price to book is 4.8, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 294.60 | 305.21 | 297.45 | 301.79 | 679,782 |
| 08 October 2026 | 297.01 | 298.27 | 288.43 | 298.00 | 1M |
| 07 October 2026 | 303.38 | 305.18 | 294.28 | 300.30 | 1M |
| 06 October 2026 | 319.80 | 333.30 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Charles River supports preclinical research — laboratory animals, disease models and drug safety testing.
Before a drug reaches humans it is tested for safety, and the regulator requires specific procedures. The company supplies the research animals, the laboratories and the specialists — a stage a developer finds cheaper to outsource than to maintain.
Demand depends on how many programmes the industry is starting, and that in turn on the availability of money at biotech start-ups and on large pharmaceutical budgets. A separate factor is regulators gradually accepting alternative methods in place of animal testing. Risks: shrinking research budgets and ethical pressure. The company pays no dividend.
Address:251 BALLARDVALE ST, WILMINGTON, MA, 01887, US
Charles River Laboratories International, Inc. reported revenue of 4.0B $ and a net loss of 185M $ over the last four quarters. Net margin is −4.59 %. Revenue changed by +0.11 % year over year. Earnings per share are −3.71 $. Market capitalisation is 14.1B $.
CRL has a return on equity of −6.28 %, above the sector median of −41.68 %. Return on assets is −2.39 %, above the sector median of −32.11 %. Operating margin is 1.75 %, above the sector median of −26.84 %.
| 146M |
| BIAFbioAffinity Technologies, Inc. | 4.69 | −16.84 % | 67M |
| ABSIAbsci Corporation | 10.14 | +13.37 % | 39M |
| OABIOmniAb, Inc. | 4.79 | +2.79 % | 7M |
| NRCNRC Health | 20.33 | −0.44 % | 3M |
| 300.01 |
| 304.96 |
| 2M |
| 05 October 2026 | 292.05 | 312.26 | 292.02 | 310.77 | 1M |
| 02 October 2026 | 287.91 | 290.61 | 285.75 | 290.19 | 443,500 |
| 01 October 2026 | 291.86 | 297.00 | 284.61 | 286.83 | 823,000 |
| 30 September 2026 | 296.97 | 298.98 | 293.46 | 295.01 | 794,100 |
| 29 September 2026 | 294.71 | 298.20 | 289.38 | 295.96 | 661,400 |
| 28 September 2026 | 289.13 | 296.88 | 289.13 | 294.59 | 900,000 |
| 25 September 2026 | 293.19 | 295.23 | 287.23 | 292.84 | 838,300 |
| 24 September 2026 | 277.00 | 298.40 | 276.95 | 294.44 | 2M |
| 23 September 2026 | 283.85 | 291.09 | 276.64 | 277.33 | 2M |
| 22 September 2026 | 280.19 | 290.11 | 277.41 | 285.11 | 1M |
| 21 September 2026 | 279.37 | 281.63 | 275.88 | 279.01 | 952,900 |
| 18 September 2026 | 281.26 | 283.00 | 276.00 | 278.06 | 1M |
| 17 September 2026 | 280.11 | 285.58 | 274.40 | 281.67 | 809,800 |
| 16 September 2026 | 272.78 | 282.91 | 270.88 | 273.41 | 1M |
| 15 September 2026 | 272.27 | 276.09 | 269.93 | 272.88 | 983,700 |
| 14 September 2026 | 278.27 | 279.64 | 267.27 | 273.11 | 1M |